Monday, 26 Aug 2019

You are here

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

SLE patients seen in the lupus clinic had significantly better overall quality measure performance (85.8% versus 70.2%; P = 0.001).

Differences between the 2 groups showed that the lupus clinic outperformed the general rheumatology clinic in:

  • sunscreen counseling (98.7% and 83.6%; P = 0.001)
  • antiphospholipid antibody testing (71.4% and 37%; P < 0.001)
  • pneumococcal vaccination (84.8% and 48.8%; P < 0.001)
  • bone mineral density testing (94.2% and 54.5%; P < 0.001)
  • drug counseling (92.2% and 80.8%, P = 0.04)
  • steroid‐sparing (100% and 82%;P < 0.007);
  • angiotensin‐converting enzyme inhibitor use (94.4% and 58.3%; P = 0.03)
  • cardiovascular disease risk assessment (40.3% and 15.1%; P = 0.01).
  • They found a moderate correlation between physician volume and quality measure performance (ρ = 0.48, P < 0.001).

A dedicated lupus clinic appears to provide more comprehensive lupus care. These measures need to be considered by general rheumatologist for enhanced incorporation into their practices or alternatively consider the need for a focused lupus clinic in their overall care model. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.